Although using ICBs as mono or combination therapies (e.g. PD-1/PD-L1 and CTLA-4) have shown promising results in a few types of cancers, success requires a deeper understanding of the TME and factors that can be targeted to enhance antitumor immune responses. Here, CTLA4 is linked to cancer.